422 results on '"Kamal, Maud"'
Search Results
2. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway
3. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
4. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
5. Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome
6. Genomics to select treatment for patients with metastatic breast cancer
7. Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial
8. Real-world performance of the digital drug-assignment system for precision oncology in lung cancer.
9. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
10. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity
11. Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort.
12. Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
13. Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
14. Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons
15. Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study.
16. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity
17. Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors.
18. Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
19. Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
20. A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
21. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients
22. Molecular characterisation of tumours of the lacrimal apparatus
23. #438 Molecular alterations predictive of outcome in early staged cervical cancer : a translational investigation from the SENTICOL III trial
24. MET functions in tumour progression and therapy resistance are repressed by intronic polyadenylation
25. Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie
26. Challenges for the Clinical Implementation of Precision Medicine Trials
27. Genomic characterization of metastatic breast cancers
28. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)
29. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
30. Abstract 3363: Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery
31. Abstract 4534: National Multidisciplinary Tumor Board improves diagnostic stratification and therapeutic management in Cancers of Unknown Primary: the French Experience
32. Angiotensin II receptors' modulation of calcium homeostasis in human vascular endothelial cells
33. supplementary table 2 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
34. supplementary table 4 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
35. supplementary table 1 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
36. supplementary table 3 from PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
37. Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer
38. RAIDS atlas of significant genetic and protein biomarkers in cervical cancer
39. Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
40. sj-docx-1-tam-10.1177_17588359221146132 – Supplemental material for Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
41. sj-pptx-2-tam-10.1177_17588359221146132 – Supplemental material for Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
42. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
43. Molecular screening programs in different countries: what we learned and perspectives
44. Cancers de primitif inconnu : une réunion de concertation pluridisciplinaire nationale pour orienter le diagnostic et la prise en charge thérapeutique
45. 2022-RA-205-ESGO Circulating HPV DNA in cervical cancer: a marker for early detection of relapse
46. Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
47. Molecular profiling in precision medicine oncology
48. Abstract 2774: Reference free transcriptomic characterization of chemoresistant triple negative breast cancers provides a promising reservoir of predictive biomarkers of early chemoresistance
49. Abstract 1237: Randomized phase II trial of pre-operative afatinib in non-metastatic head and neck squamous cell carcinoma patients: Identification of predictive biomarkers of response
50. Abstract 2105: PD-L1 high ICOSL low Secretory dendritic cells infiltrate human solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.